{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-108868","form_type":"8-K","ticker":"SPRB","cik":"0001683553","company_name":"SPRUCE BIOSCIENCES, INC.","filed_at":"2025-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.640608+00:00","generated_at":"2026-05-17T13:15:25.487903+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Spruce Biosciences Q2 net loss $2.1M; TA-ERT BLA for MPS IIIB on track Q1 2026","bullets":["Net loss of $2.1M for Q2 2025 vs $9.2M in Q2 2024; cash $16.4M expected to fund through end of 2025.","Integrated TA-ERT data shows CSF HS-NRE reduced 91.5 ng/mL at 240 weeks (p<0.0001); cognition stabilized vs decline in untreated.","First patient dosed in Phase 2 TAMARIND trial of tildacerfont for MDD; topline results expected 1H 2026.","BLA submission for TA-ERT under accelerated approval pathway anticipated Q1 2026; potential first disease-modifying therapy for MPS IIIB.","Nasdaq relisting expected after maintaining minimum bid price for 20 consecutive trading days following 1-for-75 reverse stock split."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-108868","json":"https://secwatch.observer/filing/0000950170-25-108868.json","markdown":"https://secwatch.observer/filing/0000950170-25-108868.md","text":"https://secwatch.observer/filing/0000950170-25-108868.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1683553/000095017025108868/0000950170-25-108868-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1683553/000095017025108868/sprb-20250814.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:15:25.487903+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}